【摘要】 目的评价顺铂联合多西他赛同步放化疗治疗中晚期宫颈癌的效果。方法回顾性分析80例中晚期宫颈癌患者的临床资料,依据治疗方法的不同将患者分为同步放化疗组(顺铂联合多西他赛同步放化疗)和单纯放疗组,每组40例。统计并比较两组患者的临床疗效和不良反应发生情况。结果同步放化疗组患者的治疗总有效率为70.0%(28/40),高于单纯放疗组的45.0%(18/40),差异有统计学意义(P﹤0.05)。同步放化疗组患者的胃肠道反应、放射性膀胱炎、放射性直肠炎、骨髓抑制发生率分别为95.0%(38/40)、50.0%(20/40)、52.5%(21/40)、92.5%(37/40),高于单纯放疗组的72.5%(29/40)、27.5%(11/40)、30.0%(12/40)、72.5%(29/40),差异均有统计学意义(P﹤0.05)。结论顺铂联合多西他赛同步放化疗治疗中晚期宫颈癌的效果较单纯放疗好,值得临床推广应用。更多还原

【Abstract】 Objective To evaluate the effect of cisplatin combined with docetaxel in the treatment of advanced cervical cancer. Method 80 cases of patients with advanced cervical cancer were retrospectively analyzed, by treatment delivered, these patients were stratified as concurrent chemoradiotherapy group(cisplatin plus docetaxel) and simple radiotherapy group, with 40 cases in each. The clinical efficacy, incidences of adverse reactions in the two groups were statistically analyzed. Result The overall response rate of the concurrent chemoradiotherapy group was 70.0%(28/40), and was significantly higher than that of the radiotherapy group at 45.0%(18/40)(P<0.05). The incidence of gastrointestinal reaction,radiation cystitis, radiation proctitis, and bone marrow suppression in the concurrent chemoradiotherapy group was 95.0%(38/40), 50.0%(20/40), 52.5%(21/40), and 92.5%(37/40), respectively, which were significantly higher than those in the radiotherapy group at 72.5%(29/40), 27.5%(11/40), 30.0%(12/40), and 72.5%(29/40), with significant differences observed(P<0.05). Conclusion The concurrent chemoradiotherapy of cisplatin combined with docetaxel is superior to radiotherapy alone in the treatment of advanced cervical cancer, and is clinically applicable.更多还原